Related Experiment Video
Updated: Jan 4, 2026
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
Published on: November 13, 2012
Kunitz type protease inhibitor from the canine tapeworm as a potential therapeutic for melanoma
Shiwanthi L Ranasinghe1, Vanessa Rivera2, Glen M Boyle3
1Molecular Parasitology Laboratory, Immunology Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia. shiwanthi.ranasinghe@qimrberghofer.edu.au.
Abstract:
Modulating the tumor microenvironment to promote an effective immune response is critical in managing any type of tumor. Melanoma is an aggressive skin cancer and the incidence rate is increasing worldwide. Potent protease inhibitors have recently been extensively researched as potential therapeutic agents against various cancers. EgKI-1 is a potent Kunitz type protease inhibitor identified from the canine tapeworm Echinococcus granulosus that has shown anti-cancer activities in vivo. In this study we show that EgKI-1 significantly reduced the growth of melanoma in the B16-F0 mouse model and was not toxic to normal surrounding tissue. Moreover, EgKI-1 treatment significantly reduced survivin expression levels and increased the CD8+ T cell population in draining axillary lymph nodes. Therefore, EgKI-1 potentially reduces tumor growth by inducing apoptosis and modulating the tumor microenvironment, and has potential for development as an intra-lesional treatment for melanoma.
Insights
EgKI-1, a protease inhibitor from Echinococcus granulosus, effectively reduced melanoma growth in mice without toxicity. It also modulated the tumor microenvironment by reducing survivin and increasing CD8+ T cells, showing potential for melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Modulating the tumor microenvironment is crucial for effective cancer immunotherapy.
- Melanoma incidence is rising globally, necessitating novel therapeutic strategies.
- Protease inhibitors are being investigated for their anti-cancer potential.
Purpose of the Study:
- To evaluate the efficacy of EgKI-1, a Kunitz-type protease inhibitor, against melanoma.
- To investigate the effects of EgKI-1 on tumor growth, toxicity, and the tumor microenvironment in a preclinical model.
Main Methods:
- Utilized the B16-F0 mouse melanoma model.
- Administered EgKI-1 and assessed tumor growth and tissue toxicity.
- Quantified survivin expression and CD8+ T cell populations in lymph nodes.
Main Results:
- EgKI-1 significantly inhibited melanoma tumor growth.
- No significant toxicity was observed in normal surrounding tissues.
- EgKI-1 treatment led to reduced survivin levels and increased CD8+ T cell infiltration.
Conclusions:
- EgKI-1 demonstrates anti-melanoma activity by potentially inducing apoptosis and enhancing anti-tumor immunity.
- EgKI-1 shows promise as a potential intra-lesional treatment for melanoma.
